Brief: Revive Therapeutics Clarifies Status Of Its Phase 3 Clinical Trial For Bucillamine In Covid-19
06/01/2022 22:05
Jan 6 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS CLARIFIES STATUS OF ITS PHASE 3
CLINICAL
TRIAL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - EXPECTED TO BEGIN SUBJECT
ENROLLMENT
IN TURKEY BY MID-FEBRUARY
* REVIVE THERAPEUTICS LTD - EXPECTED TO COMPLETE ENROLLMENT
IN
Q1-2022
* REVIVE THERAPEUTICS LTD - IS NOT MAKING ANY EXPRESS OR
IMPLIED
CLAIMS THAT ITS PRODUCT HAS ABILITY TO ELIMINATE OR CURE
COVID-19 AT THIS TIME
Source text for Eikon: ID:nGNXbpSSN9
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure